Skip to main content
INVENTISBIO CO., LIMITED. logo

INVENTISBIO CO., LIMITED. — Investor Relations & Filings

Ticker · 688382 ISIN · CNE100005Q22 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 446 across all filing types
Latest filing 2024-08-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688382

About INVENTISBIO CO., LIMITED.

https://www.inventisbio.com/

InventisBio Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and metabolic diseases. Its research and development pipeline includes several high-potential candidates, such as befotertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, and garsorasib, a potent KRAS G12C inhibitor. Additionally, the company is developing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a selective URAT1 inhibitor for the treatment of hyperuricemia and gout. InventisBio leverages its proprietary drug discovery platform and global clinical development expertise to advance a diverse portfolio of targeted therapies aimed at improving patient outcomes through precision medicine.

Recent filings

Filing Released Lang Actions
益方生物关于拟变更会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by a company about the proposed change of its auditing firm for the upcoming fiscal year. It details the new auditor's credentials, the reasons for the change, communication with the previous auditor, and the approval process by the audit committee and board of directors. There are no financial statements or detailed audit reports included, only information about the auditor change and related procedural approvals. The document length is under 5,000 characters and it serves as a formal announcement rather than the audit report itself. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other specific categories.
2024-08-22 Chinese
益方生物第二届董事会2024年第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of 益方生物科技（上海）股份有限公司. It details the convening of the board meeting, attendance, and the approval of specific proposals related to the use of idle raised funds and stock incentive plan vesting. It references other announcements for detailed content but itself is a summary of board decisions. There is no financial data, no full report, no voting results from a shareholder meeting, and no mention of regulatory filings or certifications. The content fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management. The document length is short (1032 characters), consistent with a board meeting resolution announcement rather than a full report or detailed filing.
2024-08-22 Chinese
益方生物关于召开2024年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about the convening of the 2024 first extraordinary general meeting of shareholders (临时股东大会) for a company, including details about the meeting date, voting methods, agenda items, and instructions for shareholders. It does not contain financial statements or detailed financial data but rather logistical and procedural information about the meeting. The document is relatively short (3285 characters) and serves as an announcement for the meeting rather than a report or results. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting itself and not the solicitation materials or voting results, it is best classified as a Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to provide information and request votes for meetings.
2024-08-22 Chinese
益方生物第二届监事会2024年第六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of the company Yifang Bio-Technology (Shanghai) Co., Ltd. It details the meeting held on August 22, 2024, including the approval of the 2024 semi-annual report and related fundraising usage reports, as well as changes to fundraising investment projects. The document is a formal announcement of meeting decisions and approvals, not the actual semi-annual report or financial statements themselves. The length is short (1025 characters), and it serves as a meeting resolution announcement rather than a full financial report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution notice rather than an Interim/Quarterly Report (IR) or Annual Report (10-K).
2024-08-22 Chinese
益方生物关于变更公司注册资本并修订《公司章程》的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from a company regarding changes to its registered capital and amendments to its Articles of Association (公司章程). It details the increase in share capital due to the vesting of restricted stock awards and the corresponding updates to the company's charter. The document is relatively short (1178 characters) and serves as a formal notification of these corporate changes. It does not contain financial statements, audit information, or detailed financial analysis. It is not a full report like an Annual Report or Interim Report, nor is it a call transcript or earnings release. The content fits the category of a Share Issue/Capital Change announcement, as it concerns changes in registered capital and share count. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2024-08-22 Chinese
君合律师事务所上海分所关于益方生物2022年限制性股票激励计划预留授予部分第一个归属期归属条件成就的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the achievement of vesting conditions for a restricted stock incentive plan of a company. It details the approval process, vesting conditions, and compliance with relevant laws and regulations. The document is not a financial report, earnings release, or management discussion, but a legal opinion related to stock incentive plan implementation and compliance. It is not an announcement of voting results or a proxy statement, but a formal legal opinion letter. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance/legal document that does not fit other specific categories.
2024-08-22 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.